Publications 2019

1. Swider E, Maharjan S, Houkes K, van Riessen NK, Figdor C, Srinivas M, Tagit O. Forster Resonance Energy Transfer-Based Stability Assessment of PLGA Nanoparticles in Vitro and in Vivo. 2019. 2(3): 1131-40.

2. Logtenberg MEW, Jansen JHM, Raaben M, Toebes M, Franke K, Brandsma AM, Matlung HL, Fauster A, Gomez-Eerland R, Bakker NAM, van der Schot S, Marijt KA, Verdoes M, Haanen J, van den Berg JH, Neefjes J, van den Berg TK, Brummelkamp TR, Leusen JHW, Scheeren FA, Schumacher TN. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPalpha axis and a target for cancer immunotherapy. Nat Med, 2019.

3. Mons E, Jansen IDC, Loboda J, van Doodewaerd BR, Hermans J, Verdoes M, van Boeckel CAA, van Veelen PA, Turk B, Turk D, Ovaa H. The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K. 2019.

4. Baranov MV, Bianchi F, Schirmacher A, van Aart MAC, Maassen S, Muntjewerff EM, Dingjan I, Ter Beest M, Verdoes M, Keyser SGL, Bertozzi CR, Diederichsen U, van den Bogaart G. The Phosphoinositide Kinase PIKfyve Promotes Cathepsin-S-Mediated Major Histocompatibility Complex Class II Antigen Presentation. iScience, 2019. 11: 160-77.

5. van Grinsven E, Textor J, Hustin LSP, Wolf K, Koenderman L, Vrisekoop N. Immature Neutrophils Released in Acute Inflammation Exhibit Efficient Migration despite Incomplete Segmentation of the Nucleus. J Immunol, 2019. 202(1): 207-17.

6. Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, Angelucci E, Stolzel F, Potter V, Yakoub-Agha I, Koc Y, Ciceri F, Finke J, Labussiere-Wallet H, Cascon MJP, Verbeek M, Rambaldi A, Cornelissen JJ, Chevallier P, Radia R, Nagler A, Fegueux N, Gluckman E, de Witte T, Kroger N. HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. Biol Blood Marrow Transplant, 2019. 25(1): 114-20.

7. Waiczies S, Srinivas M, Flogel U, Boehm-Sturm P, Niendorf T. Special issue on fluorine-19 magnetic resonance: technical solutions, research promises and frontier applications. MAGMA, 2019. 32(1): 1-3.

8. de Witte T. Effective oral hypomethylating drugs in intermediate-risk or high-risk myelodysplasia: a breakthrough?. Lancet Haematol, 2019. 6(4): e170-e1.